Significant Purchase Order from a Leading Hospital
Catheter Precision, Inc. (NYSE: VTAK), a pioneering medical device company based in the U.S., has made headlines by securing a crucial purchase order for its innovative VIVO product from a prestigious European hospital. This transaction marks an essential step for the company as it expands its footprint in the cardiac electrophysiology market.
Partnership with a Key Healthcare Institution
The purchase order is from Sahlgrenska University Hospital, the largest hospital in Sweden, which caters to approximately 350,000 patients annually. This hospital is renowned not only for its extensive patient care but also for hosting the largest ventricular ablation program in the region, making it a prime partner for Catheter Precision.
Innovation at the Heart of Electrophysiology
David Jenkins, the CEO of Catheter Precision, expressed enthusiasm about this partnership, noting the hospital's commitment to excellence in cardiac care. "We are thrilled to collaborate with Sahlgrenska University Hospital. They conduct numerous ventricular ablation procedures each year and are dedicated to training new physicians. This enables us to introduce our products to new practitioners, paving the way for future sales as these professionals advance in their careers," he stated.
Introducing VIVO to the Healthcare Market
The VIVO™ (View Into Ventricular Onset) is a cutting-edge non-invasive 3D imaging system designed to assist physicians in pinpointing the origins of ventricular arrhythmias before procedures. This innovative technology not only streamlines workflow but also significantly reduces the duration of procedures, enhancing patient care and outcomes. The system has gained recognition, receiving both U.S. FDA marketing clearance and the CE Mark, affirming its safety and efficacy.
About Catheter Precision
Founded with a mission to advance cardiac care, Catheter Precision is an innovative company focused on developing state-of-the-art solutions that enhance the treatment of cardiac arrhythmias. By working closely with healthcare professionals, the company continuously seeks to improve its offerings and adopt new technologies that revolutionize electrophysiology procedures.
Looking Ahead: The Future of Cardiac Care
Catheter Precision's strategic decision to engage with significant hospitals like Sahlgrenska not only benefits their business but also enhances the quality of care provided to patients suffering from heart conditions. By fostering educational environments in hospitals, the company creates lasting partnerships that can influence the future landscape of cardiac treatments.
Commitment to Innovation and Excellence
The commitment to innovative practices and technology positions Catheter Precision, Inc. as a leader in the medical device space. The company’s focus on collaboration with healthcare institutions and professionals allows for a robust feedback loop, paving the way for enhancements and new products that cater directly to the needs of physicians and patients alike.
Frequently Asked Questions
What is Catheter Precision, Inc. known for?
Catheter Precision, Inc. specializes in creating advanced medical devices to improve treatments for heart arrhythmias.
What is VIVO?
VIVO is a non-invasive 3D imaging system that helps physicians identify the source of ventricular arrhythmias before procedures.
Where is the first purchase order for VIVO received?
The first purchase order for VIVO was received from Sahlgrenska University Hospital in Sweden.
Who is the CEO of Catheter Precision, Inc.?
David Jenkins is the CEO of Catheter Precision, Inc.
Why is the partnership with Sahlgrenska significant?
The partnership is significant because Sahlgrenska University Hospital has a large ventricular ablation program and is dedicated to training future physicians, expanding VIVO's reach in cardiac care.
